CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 165 enrolled
Drug / intervention
Absnow Absorbable ASD Closure Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03601039
NCT03601039N/ACompleted

Evaluation of Safety and Efficacy of the Absnow Absorbable ASD Closure System For Treating ASD Patients

Lifetech Scientific (Shenzhen) Co., Ltd.·interventional·Posted Jul 26, 2018·Updated Mar 10, 2026

In Brief

A clinical study evaluating Absnow Absorbable ASD Closure System for Heart Septal Defects, Atrial and Atrial Septal Defect. Completed, enrolled 165 participants across 14 sites.

Detailed Summary

The aim of this study is to evaluate the safety and efficacy of Absnow absorbable ASD closure system for treating patients with atrial septal defect.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 26, 2018
Enrollment StartAug 25, 2018
Primary CompletionAug 28, 2020
Study CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.9 years ago

Interventions

Absnow Absorbable ASD Closure Systemdevice

the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.